Clinical Trial Update: HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata [Phase 1]

View source ↗

Summary

HCW Biologics is recruiting for a Phase 1 trial of HCW9302, an interleukin-2 fusion protein, to treat alopecia areata.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alopecia Areata

Drugs mentioned

• HCW9302 (Interleukin-2 fusion protein)

Snippet

Sponsor: HCW Biologics | Conditions: Alopecia Areata(AA) | Phase 1 | Status: RECRUITING